Your browser doesn't support javascript.
loading
Reply to the letter to the editor 'clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC' by Ou et al.
Ou, S-H I; Pasi, J.
Affiliation
  • Ou SI; Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange. Electronic address: siou@uci.edu.
  • Pasi J; Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
Ann Oncol ; 25(10): 2093, 2014 Oct.
Article in En | MEDLINE | ID: mdl-25035278
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Pyridines / Receptor Protein-Tyrosine Kinases / Carcinoma, Non-Small-Cell Lung Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2014 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Pyridines / Receptor Protein-Tyrosine Kinases / Carcinoma, Non-Small-Cell Lung Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2014 Document type: Article